Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease

What this episode covers

For the complete activity, including supporting material, please visit https://www.peervoice.com/YWG860. Presented by Hannele Yki-Järvinen, MD, FRCP and Cyrielle Caussy, MD, PhD. Learning Objectives: Recognise the bidirectional relationship between type 2 diabetes (T2D) and metabolic dysfunction-associated steatohepatitis (MASH), including the impact of MASH on glycaemic control, insulin resistance, and complications; Explain the rationale for prompt identification and active management of individuals with MASH and fibrosis, based on the increased risk of adverse liver outcomes associated with progression of fibrosis; Evaluate the impact of novel liver-directed therapies, such as thyroid hormone receptor beta (THR-β) agonists, on the underlying pathophysiology and progression of the disease, including in individuals receiving treatment for T2D; List appropriate non-invasive tests for determining the presence of liver steatosis and fibrosis in endocrinology patients at increased risk for MASH.